Adynxx, Inc

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. Show More...

  • Website http://www.adynxx.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 0.00 USD
  • Last Updated 25-04-2024
  • External Links Yahoo Finance Morningstar Ratios
  •   2009-12 2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 TTM
    Earnings Per Share USD -26.25 -52.5 -183.75 -54.6 -188.4 -104.4 -67.8 -60.6 -35.94 -10.26 -4.08
    Dividends USD
    Payout Ratio % *
    Shares Mil 1.0 1.0 3.0
    Book Value Per Share * USD 325.94 299.0 123.05 59.26 96.73 118.41 98.36 32.56 11.44 -1.9
    Free Cash Flow Per Share * USD -29.74 -29.86 -22.87 -35.32 -56.18 -60.9 -41.76 -22.97 -10.48
    Return on Assets % -102.87 -22.49 -70.64 -35.35 -143.94 -107.88 -43.55 -39.16 -58.8 -39.5 -129.47
    Financial Leverage (Average) 1.05 1.02 1.03 1.13 1.25 1.32 1.71 1.7 2.1 1.17
    Return on Equity % -110.89 -22.89 -72.05 -38.05 -171.92 -139.57 -69.44 -66.84 -107.66 -70.38
    Return on Invested Capital % -111.61 -22.94 -72.06 -38.03 -171.91 -139.73 -50.62 -49.71 -69.31 -70.58
    Interest Coverage -16.72 -12.03 -11.53
    Current Ratio 23.91 6.12 1.79 0.59 3.83 4.75 2.77 0.58 0.44 6.76 0.18
    Quick Ratio 23.46 4.47 0.97 0.25 3.66 4.3 2.43 0.41 0.32 6.48 0.02
    Debt/Equity 0.23